
Amryt Pharma’s Filsuvez®, the first EB-specific treatment designed to heal partial thickness wounds in Dystrophic and Junctional EB in patients 6 months and older, has been approved by the European Commission (EC) for use in the EU. This means that the treatment has been declared safe for use in humans within the EU.
Read More